CN103450142B - Chroman compound as well as extracting method and application thereof - Google Patents
Chroman compound as well as extracting method and application thereof Download PDFInfo
- Publication number
- CN103450142B CN103450142B CN201310397862.8A CN201310397862A CN103450142B CN 103450142 B CN103450142 B CN 103450142B CN 201310397862 A CN201310397862 A CN 201310397862A CN 103450142 B CN103450142 B CN 103450142B
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- chroman compound
- chroman
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a chroman compound as well as an extracting method and application thereof. The chroman compound is R-3-methyl-6, 8-dihydroxy-7-methyl-3, 4-dihydroisochromen-1-one (R-3-methyl-6, 8-dihydroxy-7-methyl-3, 4-dihydroisochromen-1-ketone). The extracting method of the compound comprises the following steps of: leaching ground beetles in an organic solvent to obtain a leaching solution, concentrating the leaching solution and adding water to prepare water suspension; extracting the water suspension, concentrating an extracting solution to obtain an extract; and separating and purifying from the extract to obtain the chroman compound. According to the invention, the chroman compound with a novel structure is separated and identified from the ground beetles, has wide pharmacological activity, and can be used for preparing anti-tumor drugs or tumor-preventing healthcare food, antityrosinase drugs or whitening cosmetics.
Description
Technical field
The present invention relates to active ingredient of Chinese herbs field, particularly relate to a kind of chroman compound and extracting method thereof and application.
Background technology
Eupolyphoge sinensis (ground beetle): another name Eupolyphaga Seu Steleophaga, ground beetle, excessively street, DIWUGUI, joint joint worm, Cimex bedbug mother, eupolyphaga.Belong to insecticide, health is flat, brownish black, and male worm has wing, and female worm is aptery.Be everlasting house the foot of a wall soil in movable, can be used as medicine.Also cry and sting worm, common name ground beetle.In Chinese medicine, alleged Eupolyphaga Seu Steleophaga generally refers to the female worm dry body of Corydiidae insecticide eupolyphoge sinensis (Eupolyphaga sinensis Walker) or Ji eupolyphoge sinensis (Steleophaga plancyi).
Traditional Chinese Medicine thinks that Eupolyphaga Seu Steleophaga has effect of removing blood stasis, reunion of fractured tendons and bones, and has corroded rock mass.Can be used for treatment traumatic injury, injury of tendon and muscle fracture, pain caused by ecchymoma, the diseases such as blood stasis amenorrhea, the stagnant stomachache of the stasis of blood in puerperal, lump in the abdomen mass in the abdomen.
The chemical composition of Eupolyphaga Seu Steleophaga extractum is analyzed, finds that its main component comprises multiple volatile oil, aminoacid, protein, fat, steroid, phenols, organic acid, alkaloid and trace mineral element.
Carry out pharmacology analysis discovery to Eupolyphaga Seu Steleophaga extractum, the pharmacological action of Eupolyphaga Seu Steleophaga extractum comprises: cardiovascular system is had to the effects such as anticoagulation, antithrombotic, adjusting blood lipid, antioxidant radical, protection vascular endothelial cell, ischemia resisting anoxia; There is obvious mutation ability, show anti-frame shift type gene mutation ability especially; The expression of Bone formation-related gene in osteoblast cultured in vitro can be promoted, promote the healing of bone injury, reach the object for the treatment of trauma fracture; Red blood cell cr1 activity can be improved, strengthen its immunoadsorption function; Hepatocyte can be protected, alleviate hepatocellular degeneration necrosis, reduce proliferation of fibrous tissue, promote fibrous tissue degraded; Aortic smooth muscle cell proliferation is suppressed by suppressing the expression of platelet derived growth factor (PDGF); In eupolyphoge sinensis polypide, be separated the Eupolyphaga Seu Steleophaga active fibring (EFP) that obtains can Tumor suppression angiogenesis, has the effect of vitro inhibition human esophagus cancer cell strain Eca109 and cervical cancer cell lines Hela.
According to the literature, in recent years in areas such as China, Thailand, India and Malaysia, Eupolyphaga Seu Steleophaga is also used by as tonic.
Eupolyphaga Seu Steleophaga has pharmacologically active widely, is that the preparation clinical indication of compound recipe relates to cardiovascular and cerebrovascular disease, hepatopathy, gynecological, trauma pain, diabetes, tumor and sub-healty adults Blood stasis etc. with Eupolyphaga Seu Steleophaga.But its pharmacologically active widely relatively, the research of its effective active composition is just at the early-stage.At present, except large class routine chemical components several in eupolyphoge sinensis polypide, the effective active composition obtaining identifying is also few, and research is comparatively it is clear that active fibring EFP and pharmacological action thereof.
Summary of the invention
The invention provides a kind of chroman compound, this compound is from Eupolyphaga Seu Steleophaga, extract the natural active matter obtained, and has pharmacologically active widely.
A kind of chroman compound, structural formula is:
Described chroman compound is that extraction and isolation obtains from Eupolyphaga Seu Steleophaga, systematic naming method is R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydroisochromen-1-one(R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone).
Present invention also offers a kind of extracting method of described chroman compound, comprising:
(1) Eupolyphaga Seu Steleophaga is placed in organic solvent lixiviate, obtains lixiviating solution;
(2) add water after lixiviating solution being concentrated and prepare aqueous suspension, aqueous suspension is extracted, extract is concentrated, obtain extractum;
(3) from extractum, separation and purification obtains described chroman compound.
Described Eupolyphaga Seu Steleophaga is the female worm dry body of Corydiidae insecticide eupolyphoge sinensis (Eupolyphaga sinensis Walker) or Ji eupolyphoge sinensis (Steleophaga plancyi).Described female worm can obtain from wild environment, also can obtain through artificial propagation.
Described Eupolyphaga Seu Steleophaga directly can be placed in or be placed in organic solvent lixiviate after crushed, carries out the leaching that lixiviate is more conducive to Eupolyphaga Seu Steleophaga activity in vivo composition after pulverizing.
The method that described lixiviate adopts is cold-maceration or water bath reflux method.
Described cold-maceration is container Eupolyphaga Seu Steleophaga being put into sealing, adds the organic solvent of certain volume by formula, soaks about 2 weeks.Period often shakes, and be fully dissolved into after in organic solvent until the active component in eupolyphoge sinensis polypide, filtration can obtain lixiviating solution.
Described water bath reflux method is application organic solvent heating extraction, need adopt reflux device, in order to avoid solvent volatilization loss.Water bath reflux method is than cold-maceration complex operation, but extraction efficiency is high.
In order to the active component in abundant lixiviate eupolyphoge sinensis polypide, the w/v (kg/L) of described Eupolyphaga Seu Steleophaga and organic solvent is 1:3 ~ 3:1, is more preferably 1:2 ~ 2:1.
Described organic solvent can be one or more in methanol, ethanol, chloroform, ethyl acetate and acetone, and preferably, described organic solvent is methanol, ethanol or their mixed liquor.The polarity of methanol and ethanol is relatively high, utilize methanol or ethanol carry out lixiviate can obtain more in the active component of low polarity.
During extraction, the solvent immiscible with the organic solvent adopted during lixiviate should be selected.As preferably, when with methanol lixiviate, ethyl acetate is adopted to extract; When using alcohol steep, chloroform is adopted to extract.Further, for improving extraction yield, adding water after preferably first lixiviating solution being concentrated and preparing aqueous suspension, then aqueous suspension is extracted.
In step (3), purification on normal-phase silica gel column chromatography can be adopted to carry out separation and purification to extractum, obtain described chroman compound.Eluant is preferably petrol ether/ethyl acetate mixed liquor, and the polarity of petroleum ether and ethyl acetate is all lower, can carry out abundant chromatography to target compound, removes whole or most of impurity; Compared with other organic solvents, petroleum ether and ethyl acetate toxicity lower, be conducive to research worker healthy.
More preferably, when carrying out purification on normal-phase silica gel column chromatography, using petrol ether/ethyl acetate mixed liquor as eluant, be specially and carry out gradient elution by petrol ether/ethyl acetate volume ratio 9:1,4:1,3:1,1:1,1:3,1:9, the fraction that collection petrol ether/ethyl acetate volume ratio elutes when being 4:1, rotation evaporate to dryness is carried out to this fraction, namely obtains described chroman compound.
For obtaining the higher target compound of purity, can be further purified the target fraction obtained through purification on normal-phase silica gel column chromatography, purification process is that recrystallization, reversed-phase silica gel column chromatography or high performance liquid chromatography are separated.
The eluant that described reversed-phase silica gel column chromatography is separated is preferably methanol/water mixed liquor; More preferably, 9:1,4:1,1:1,1:3,1:9 carry out gradient elution by volume.
Present invention also offers described chroman compound and prepare the application in antitumor drug.This antitumor drug for main active with chroman compound of the present invention, adds acceptable adjuvant on pharmaceutics and makes, can make preparation according to the formulation preparation method that pharmaceutics is recorded.Described preparation can be injection, drip liquid, injectable powder, granule, tablet, electuary, powder, oral liquid, sugar coated tablet, film coated tablet, enteric coated tablet, suck agent, granule, pill, unguentum, sublimed preparation, spray, drop pill, disintegrating agent, oral cavity disintegration tablet, micropill etc.
As preferably, described antitumor drug is medicament for resisting cervical cancer.After tested, described chroman compound is to the IC of Hela cell
50be 44 μMs, stronger growth inhibited effect is possessed to Hela cell.
Present invention also offers described chroman compound and prepare the application in tumor prevention health food.This tumor prevention health food for main active with chroman compound of the present invention, adds acceptable health food adjuvant and makes.
Present invention also offers described chroman compound and prepare the application in antityrosinase medicine or skin-lightening cosmetic.After tested, described chroman compound is to the IC of tryrosinase
50be 23 μMs, show that it has better activity inhibition to tryrosinase.
Described antityrosinase medicine for main active with chroman compound of the present invention, adds acceptable adjuvant on pharmaceutics and makes, can make preparation according to the formulation preparation method that pharmaceutics is recorded.Described preparation can be injection, drip liquid, injectable powder, granule, tablet, electuary, powder, oral liquid, sugar coated tablet, film coated tablet, enteric coated tablet, suck agent, granule, pill, unguentum, sublimed preparation, spray, drop pill, disintegrating agent, oral cavity disintegration tablet, micropill, unguentum, membranous patch, aerosol tincture, suppository, lotion, nasal drop etc.
In addition, because tryrosinase also participates in the browning reaction of fruit and vegerable, therefore utilize chroman compound of the present invention as active component, also can be used for food preservative.
Compared with prior art, beneficial effect of the present invention is:
(1) the present invention utilizes the polarity difference of chromane class material to extract from Eupolyphaga Seu Steleophaga and is separated and obtains a kind of chroman compound with novel structure, and the method is easy and simple to handle, extraction yield is high, product purity is high, is applicable to large-scale production.
(2) chroman compound provided by the invention has pharmacologically active widely, can for the preparation of antitumor drug or tumor prevention health food, antityrosinase medicine or skin-lightening cosmetic.
Accompanying drawing explanation
Fig. 1 is R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone
13c-NMR collection of illustrative plates (125MHz);
Fig. 2 is the circular dichroism spectrogram of R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone; Wherein, upper figure is CD spectrogram, and the Y-axis mdeg of CD spectrogram represents milli degree, and X-axis is wavelength nm; Figure below is ultraviolet spectrogram, and the Y-axis of ultraviolet spectrogram represents absorbance, and X-axis is wavelength nm;
Fig. 3 is the structural formula of R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone.
Detailed description of the invention
The preparation of embodiment 1 chroman compound
Get 10kg Eupolyphaga Seu Steleophaga, with 10L methanol lixiviate 2 weeks, methanol extract after concentrated with 1L distilled water suspendible, aqueous suspension 1L extraction into ethyl acetate 3 times, acetic acid ethyl acetate extract obtains extractum 23g through concentrated; Mix sample with silica gel (100 orders, 100g), carry out purification on normal-phase silica gel column chromatography (200-300 order, 1kg; Silicagel column size L500mm,
), carry out gradient elution with the petrol ether/ethyl acetate mixed liquor of volume ratio 9:1,4:1,3:1,1:1,1:3,1:9 successively, each gradient elution 5L; TLC detects fraction, and the fraction collecting eluting ratio 4:1 merges, concentrates, then uses acetone recrystallization (room temperature), namely obtains target compound.
The preparation of embodiment 2 chroman compound
Get 10kg Eupolyphaga Seu Steleophaga, use 5L alcohol reflux, alcohol extract after concentrated with 1L distilled water suspendible, aqueous suspension 1L chloroform extraction 3 times, chloroform extraction liquid obtains extractum 234g after concentrating; Mix sample with silica gel (100 orders, 100g), carry out purification on normal-phase silica gel column chromatography (200-300 order, 1kg; Silicagel column size L500mm,
), carry out gradient elution with the petrol ether/ethyl acetate mixed liquor of volume ratio 9:1,4:1,3:1,1:1,1:3,1:9 successively, each gradient elution 5L; TLC detects fraction, and the fraction collecting eluting ratio 4:1 merges, concentrates, then uses acetone recrystallization (room temperature), namely obtains target compound.
The preparation of embodiment 3 chroman compound
Get the Eupolyphaga Seu Steleophaga after 10kg pulverizing, extract with 5L methanol/ethanol mixed liquor, methanol/ethanol lixiviating solution is concentrated to obtain extractum 366g, mixes sample, 5L chloroform hot dipping 3 times, carry out purification on normal-phase silica gel column chromatography (200-300 order, 1kg with 100g kieselguhr; Silicagel column size L500mm,
), carry out gradient elution with the petrol ether/ethyl acetate mixed liquor of volume ratio 9:1,4:1,3:1,1:1,1:3,1:9 successively, each gradient elution 5L; TLC detects fraction, and the fraction collecting eluting ratio 4:1 merges, concentrates, then uses acetone/normal hexane (volume ratio 1:1) recrystallization (room temperature), namely obtains target compound.
The preparation of embodiment 4 chroman compound
Get the Eupolyphaga Seu Steleophaga after 10kg pulverizing, with the lixiviate of 5L methanol/ethanol mixed liquor, lixiviating solution concentrates, and obtains extractum 350g, mixes sample with 100g kieselguhr, 5L chloroform hot dipping 3 times, carry out purification on normal-phase silica gel column chromatography (200-300 order, 1kg; Silicagel column size L500mm,
), carry out gradient elution with the chloroform/methanol mixed liquor of volume ratio 9:1,4:1,3:1,1:1,1:3,1:9 successively, each gradient elution 5L; TLC detects fraction, and the fraction collecting eluting ratio 4:1 merges, concentrates.Fraction after concentrated carries out reversed-phase silica gel column chromatography, and eluant is followed successively by the methanol/water mixed liquor of volume ratio 9:1,4:1,1:1,1:3,1:9, each gradient elution 1L, TLC detects each fraction, merging, concentrating eluting ratio is the fraction of 4:1, with acetone recrystallization, namely obtains target compound.
Through the target fraction that purification on normal-phase silica gel column chromatography obtains, after concentrated, high performance liquid chromatography also can be utilized to carry out purification.The determined wavelength of high performance liquid chromatography is 254nm, and eluant is followed successively by 30%-100% methanol, and collecting retention time is the eluting peak of 21-22min, is merged by eluent concentrated, with acetone recrystallization, namely obtains target compound.
The Structural Identification of embodiment 5 chroman compound
Adopt HPLC to carry out Purity to obtained compound, the sample that purity is greater than 98% uses mass spectrum and nuclear magnetic resonance technique to carry out Structural Identification, and nuclear magnetic resonance, NMR Bruker AVANCE DRX-500NMR Sectrometer measures, marks in TMS does; High resolution mass spectrum FTICRMS Bruker ApexSpectrometer measures; Electrospray Mass Spectrometry ESI-MS Bruker Esquire3000
plusspectrometer measures.
This compound
13as shown in Figure 1, NMR data are as shown in table 1 for C-NMR collection of illustrative plates.
The NMR data of table 1 compound
| Position | δ C | δ H(J in Hz) |
| 1 | 170.4(s) | |
| 3 | 75.7(d) | 4.63(m) |
| 4 | 34.5(t) | 2.83(m) |
| 5 | 105.7(d) | 6.22(s) |
| 6 | 160.3(s) | |
| 7 | 109.8(s) | |
| 8 | 162.2(s) | 11.46(OH) |
| 9 | 101.3(s) | |
| 10 | 138.0(s) |
| 11 | 7.4(q) | 2.13(s) |
| 12 | 20.7(q) | 1.51(d,J=6.5) |
HR-TOF-MS shows molecular ion peak m/z208.0744(calcd.208.0736), illustrate that molecular formula is C
11h
12o
4.Connexus modal data to carry out analysis to the NMR collection of illustrative plates of this compound and circular dichroism spectra (as shown in Figure 2) known, this compound is chroman compound, systematic naming method is: R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydroisochromen-1-one(R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone), molecular formula is C
12h
14o
4, structure is as follows:
Embodiment 6 chroman compound anti-tumor activity is analyzed
Hela cell culture is in the RP-MI1640 culture medium containing 10% calf serum, penicillin 100IU/mL and streptomycin 100g/mL, and every 3d changes liquid 1 time, and every 5d goes down to posterity 1 time.Cell is all placed in 37 DEG C.To take the logarithm trophophase cell, be diluted to 5 × 10 with RPMI1640 culture medium
4/ mL single cell suspension, is inoculated in 96 porocyte culture plates, each concentration multiple cropping 3 hole, every hole 180 μ L.After putting incubator incubation 12h, the every hole of medicine group adds variable concentrations test liquid 20 μ L, parallelly establishes blank group (replacing test medicine by isopyknic RPMI1640 culture medium), Dual culture 48h.Every hole adds 1mg/mL MTT solution 50 μ L, and after continuing to cultivate 4h, exhaust supernatant, every hole adds dimethyl sulfoxide (DMSO) 150 μ L, fully dissolves MTT reduzate.Put the optical density (D) microplate reader measuring each medicine group and blank group in 492nm wavelength place, obtain suppression ratio (IR, %) and the half-inhibition concentration (IC of drug on tumor Growth of Cells by formulae discovery
50), and preliminary evaluation is carried out to drug effect.
IR(%)=(the average D value of 1-dosing group average D value/matched group) × 100%.
Experimental result is known, the IC of this compound
50=44 μMs (Hela cell), shows that this compound has good antitumor action.
Embodiment 7 chroman compound is to tyrosinase inhibitory activity analysis
R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone is dissolved in methanol, makes final concentration be 2.5%.Under 25 DEG C of conditions, tryrosinase (28nM) is at 50nM Na-phosphate buffer (na phosphates buffer, pH6.8) and compound preincubate 10min.Then LDOPA (levodopa, 0.5mM) is added.Detect at wavelength 475nm (37 DEG C).
The inhibit activities computing formula of compound to tryrosinase is as follows:
Suppression ratio (%)=[(B – S)/B] × 100%
Wherein, B is blank absorption, and S is absorption of sample.
Known by experimental result, the IC of this compound
50=23 μMs, show that this compound is better to tyrosinase inhibitory activity.
Embodiment 8 is containing the preparation of chroman compound dropping pill formulation
Get 0.5g chroman compound R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone to mix homogeneously with 10.5g PEG-4000, heating and melting, moves in drop pill drip irrigation after material, medicinal liquid drops in 6 ~ 8 DEG C of liquid paraffin, oil removing, obtained drop pill 300.
Embodiment 9 is containing the preparation of chroman compound lyophilized injectable powder
Get chroman compound R-3-methyl-6,8-dihydroxy-7-methyl-3,4-dihydro chromane-1-ketone 0.5g, glucose 4.5g, sodium thiosulfate 0.9g and distilled water 1000mL, after said components mix homogeneously, lyophilization, subpackage 400, to obtain final product.
Claims (1)
1. a chroman compound is preparing the application in antitumor drug or tumor prevention health food, it is characterized in that, described antitumor drug is medicament for resisting cervical cancer, and described tumor prevention health food is cervical cancer prevention and health care food, and the structural formula of described chroman compound is:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410475018.7A CN104306369B (en) | 2013-09-04 | 2013-09-04 | A kind of chroman compound and its extracting method and application |
| CN201310397862.8A CN103450142B (en) | 2013-09-04 | 2013-09-04 | Chroman compound as well as extracting method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310397862.8A CN103450142B (en) | 2013-09-04 | 2013-09-04 | Chroman compound as well as extracting method and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410475018.7A Division CN104306369B (en) | 2013-09-04 | 2013-09-04 | A kind of chroman compound and its extracting method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103450142A CN103450142A (en) | 2013-12-18 |
| CN103450142B true CN103450142B (en) | 2015-03-25 |
Family
ID=49733031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310397862.8A Expired - Fee Related CN103450142B (en) | 2013-09-04 | 2013-09-04 | Chroman compound as well as extracting method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103450142B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2953938T3 (en) | 2014-02-07 | 2017-12-29 | Novogen Ltd. | Functionalised benzopyran compounds and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3306200A1 (en) * | 1983-02-23 | 1984-08-23 | Haarmann & Reimer Gmbh, 3450 Holzminden | METHOD FOR PRODUCING ISOCHROMAN DERIVATIVES |
| US6019992A (en) * | 1998-12-04 | 2000-02-01 | Chesebrough-Pond's Usa Co. | Cosmetic skin care compositions containing 4-chromanone |
| CN1754544A (en) * | 2004-09-30 | 2006-04-05 | 厦门今润医药科学开发有限公司 | Gound beetle extractions extracted from different parts and heat-free extraction process |
| EP1856083A4 (en) * | 2005-03-11 | 2009-05-27 | Univ Michigan | Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| CN1709284A (en) * | 2005-06-23 | 2005-12-21 | 南京大学医学院附属鼓楼医院 | Extraction of anti-tumour active ingredient fatty acid from ground beetle |
| CN101390881B (en) * | 2007-09-21 | 2013-06-05 | 浙江医药股份有限公司新昌制药厂 | Preparation of wood louse powder extract and uses thereof |
| CN101917989A (en) * | 2008-01-17 | 2010-12-15 | 默克专利股份有限公司 | Preparation containing chromane-2-one derivatives |
| FR2951721A1 (en) * | 2009-10-26 | 2011-04-29 | Univ Rouen | PROCESS FOR SYNTHESIZING ANALOGUES OF EPICOCCONONE |
| US9492418B2 (en) * | 2011-05-10 | 2016-11-15 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Inhibitors of PFKFB3 for cancer therapy |
-
2013
- 2013-09-04 CN CN201310397862.8A patent/CN103450142B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103450142A (en) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2829275B1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
| CN102861112B (en) | Kosteletzkya virginica lignan extract and preparation method and application thereof | |
| Hao-Cong et al. | Chemical constituents and pharmacologic actions of Cynomorium plants | |
| CN101313927A (en) | Southernwood total flavone, method for preparing its composition and medicine uses thereof | |
| CN103408528B (en) | Chroman compound, as well as preparation method and application thereof | |
| Zhang et al. | Sesquiterpenes and polyphenols with glucose-uptake stimulatory and antioxidant activities from the medicinal mushroom Sanghuangporus sanghuang | |
| CN105017345A (en) | Method for simultaneously extracting four kinds of compounds from selfheal, and application of extracted compounds | |
| CN102988457A (en) | Total flavone extract of lonicera macranthoides leaves, and preparation method and application thereof | |
| CN102030800B (en) | Abies holophylla triterpenoid compound, extraction separation thereof and application thereof | |
| CN103450142B (en) | Chroman compound as well as extracting method and application thereof | |
| CN106822331A (en) | To lock application of the lichee bark extract based on shape polymer polyphenol in treatment antihyperuricemic disease drug or health products are prepared | |
| CN102000047B (en) | Antrodia camphorata cyclonene compound for restraining growth of bone cancer cells | |
| CN103610682A (en) | Preparation method of 3(alpha)-hydroxyl-30-olive-12,20(29)-diene-28-acid and application in preparing anti-tumor drug | |
| KR102262317B1 (en) | Composition for anticancer or cancer supplement comprising root extract of Rhododendron mucronulatum | |
| CN104306369B (en) | A kind of chroman compound and its extracting method and application | |
| KR0183448B1 (en) | Anti-carcinogenic composition containing ginsenoside rg5 | |
| CN103316184A (en) | Preparation method of traditional Chinese medicine extracts | |
| CN103751269B (en) | Rabdosia rubescens extract application in alpha-glucosidase inhibitor | |
| CN109091602B (en) | Effective component of semen allii tuberosi, extraction method and application thereof in preparing liver injury protection medicine | |
| Gou et al. | Traditional uses, phytochemistry, and pharmacology of Persicaria orientalis (L.) Spach-A review | |
| CN104688798A (en) | Gypsophila oldhamiana Miq extractive preparation method and application | |
| CN103694302B (en) | 2 α, the preparation method of 3 beta-dihydroxyl-30-olea-12,20 (29)-diene-28-acid and preparing the application in antitumor drug | |
| CN102319273A (en) | Salicornia biggelowii Torr. active total saponin extract, its preparation method and its purpose of losing weight | |
| KR102297152B1 (en) | Composition for anticancer or cancer supplement comprising extracts of raw pericarp derived from immature fruit of Camellia japonica | |
| CN107602657B (en) | Withanoid I, extraction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150325 Termination date: 20150904 |
|
| EXPY | Termination of patent right or utility model |